Antipsychotic Drugs in Autistic Children using LC/MS-MS: Better-Fixed Doses Necessary for the Middle East

[1]  Marco Turi,et al.  Differential Diagnosis in Children with Autistic Symptoms and Subthreshold ADOS Total Score: An Observational Study , 2021, Neuropsychiatric disease and treatment.

[2]  J. Bobes,et al.  The usefulness of Olanzapine plasma concentrations in monitoring treatment efficacy and metabolic disturbances in first-episode psychosis , 2020, Psychopharmacology.

[3]  K. Nasserinejad,et al.  Risperidone plasma concentrations are associated with side effects and effectiveness in children and adolescents with autism spectrum disorder , 2020, British journal of clinical pharmacology.

[4]  S. Levy,et al.  Identification, Evaluation, and Management of Children With Autism Spectrum Disorder , 2019, Pediatrics.

[5]  Olanzapine , 2019, Reactions Weekly.

[6]  T. Schwartz.  Fine Tuning the Use of Second Generation Antipsychotics , 2018, JOURNAL OF MENTAL HEALTH AND CLINICAL PSYCHOLOGY.

[7]  A. Urban,et al.  Therapeutic drug monitoring of atypical antipsychotics. , 2017, Psychiatria polska.

[8]  M. Ceylan,et al.  High monocyte level and low lymphocyte to monocyte ratio in autism spectrum disorders , 2017, International journal of developmental disabilities.

[9]  Brian K. Lee,et al.  The Changing Epidemiology of Autism Spectrum Disorders. , 2017, Annual review of public health.

[10]  J. Cannell.  Vitamin D and autism, what’s new? , 2017, Reviews in Endocrine and Metabolic Disorders.

[11]  Erik L. Mortensen,et al.  In utero Exposure to β-2-Adrenergic Receptor Agonist Drugs and Risk for Autism Spectrum Disorders , 2016, Pediatrics.

[12]  P. Bolton,et al.  Heritability of autism spectrum disorders: a meta‐analysis of twin studies , 2015, Journal of child psychology and psychiatry, and allied disciplines.

[13]  Alexander M. Benison,et al.  Maternal Stress Combined with Terbutaline Leads to Comorbid Autistic-Like Behavior and Epilepsy in a Rat Model , 2015, The Journal of Neuroscience.

[14]  M. Grundmann,et al.  Therapeutic drug monitoring of atypical antipsychotic drugs , 2014, Acta pharmaceutica.

[15]  S. Heres,et al.  Pharmacokinetics of olanzapine long-acting injection: the clinical perspective , 2014, International clinical psychopharmacology.

[16]  Matthias J. Müller,et al.  AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. , 2014, Pharmacopsychiatry.

[17]  J. Mifsud,et al.  Interactions between valproic acid and quetiapine/olanzapine in the treatment of bipolar disorder and the role of therapeutic drug monitoring , 2014, The Journal of pharmacy and pharmacology.

[18]  S. Woolfenden,et al.  Iron deficiency in children with global developmental delay and autism spectrum disorder , 2014, Journal of paediatrics and child health.

[19]  Mogens Vestergaard,et al.  Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. , 2013, JAMA.

[20]  Marta García-Fiñana,et al.  The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[21]  Christopher Gillberg,et al.  Vitamin D and autism: clinical review. , 2012, Research in developmental disabilities.

[22]  C. Newschaffer,et al.  Prenatal exposure to β2-adrenergic receptor agonists and risk of autism spectrum disorders , 2011, Journal of Neurodevelopmental Disorders.

[23]  E. Spina,et al.  Pharmacokinetic drug-drug interactions between olanzapine and valproate need to be better studied. , 2010, The Journal of clinical psychiatry.

[24]  E. Spina,et al.  Effect of Valproate on Olanzapine Plasma Concentrations in Patients With Bipolar or Schizoaffective Disorder , 2009, Therapeutic drug monitoring.

[25]  E. Spina,et al.  Estimating the effects of co-medications on plasma olanzapine concentrations by using a mixed model , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[26]  H. Chaudhry,et al.  Comparison of risperidone, olanzapine and quetiapine: effects on body weight, serum blood glucose and prolactin , 2008, International psychiatry : bulletin of the Board of International Affairs of the Royal College of Psychiatrists.

[27]  B. Condron,et al.  Developmental effects of SSRIs: lessons learned from animal studies , 2007, International Journal of Developmental Neuroscience.

[28]  Julie Daniels,et al.  The epidemiology of autism spectrum disorders. , 2007, Annual review of public health.

[29]  D. Geschwind,et al.  Autism spectrum disorders: developmental disconnection syndromes , 2007, Current Opinion in Neurobiology.

[30]  S. Katz.  Has the Measles-Mumps-Rubella Vaccine Been Fully Exonerated? , 2006, Pediatrics.

[31]  M. Murray.  Role of CYP pharmacogenetics and drug‐drug interactions in the efficacy and safety of atypical and other antipsychotic agents , 2006, The Journal of pharmacy and pharmacology.

[32]  G. Dawson,et al.  Is There a ‘Regressive Phenotype’ of Autism Spectrum Disorder Associated with the Measles-Mumps-Rubella Vaccine? A CPEA Study , 2006, Journal of autism and developmental disorders.

[33]  Eric Fombonne,et al.  Pervasive developmental disorders in preschool children: confirmation of high prevalence. , 2005, The American journal of psychiatry.

[34]  Shin-Yu Lu,et al.  Initial diagnosis of anemia from sore mouth and improved classification of anemias by MCV and RDW in 30 patients. , 2004, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[35]  C. Lawler,et al.  Identifying environmental contributions to autism: provocative clues and false leads. , 2004, Mental retardation and developmental disabilities research reviews.

[36]  Mark F Blaxill,et al.  Thimerosal and autism? A plausible hypothesis that should not be dismissed. , 2004, Medical Hypotheses.

[37]  C. Sabbioni,et al.  Atypical antipsychotics: pharmacokinetics, therapeutic drug monitoring and pharmacological interactions. , 2004, Current medicinal chemistry.

[38]  Marilyn Miller,et al.  Autism and Möbius sequence: an exploratory study of children in northeastern Brazil. , 2003, Arquivos de neuro-psiquiatria.

[39]  G. Baker,et al.  Interactions between the cytochrome P450 system and the second-generation antipsychotics. , 2003, Journal of psychiatry & neuroscience : JPN.

[40]  L. Bertilsson,et al.  Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. , 2002, British journal of clinical pharmacology.

[41]  E. Spina,et al.  Newer antipsychotics: comparative review of drug interactions , 2001, Expert review of neurotherapeutics.

[42]  J. Markowitz,et al.  Drug Glucuronidation in Clinical Psychopharmacology , 2001, Journal of clinical psychopharmacology.

[43]  N. Yasui-Furukori,et al.  Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[44]  P. Asherson,et al.  Approaches to gene mapping in complex disorders and their application in child psychiatry and psychology , 2001, British Journal of Psychiatry.

[45]  M. Bourin,et al.  Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4 , 1999, Naunyn-Schmiedeberg's Archives of Pharmacology.

[46]  D W Nebert,et al.  The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. , 1997, Pharmacogenetics.

[47]  Serkan Gunes.  Modified-Release Methylphenidate-Related Trichotillomania in a Boy with Autism Spectrum Disorder. , 2017, Journal of child and adolescent psychopharmacology.